Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Denosumab Protects Bone Loss and Function in Osteopenia Patients With Lumbar Degenerative Diseases After Lumbar Fusion Surgery, a Randomized, Placebo Controlled Trial.

NCT05415657 is registered in ClinicalTrials.gov with Shenzhen People's Hospital as lead sponsor.

NCT NCT05415657
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05415657 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Denosumab Protects Bone Loss and Function in Osteopenia Patients With Lumbar Degenerative Diseases After Lumbar Fusion Surgery, a Randomized, Placebo Controlled Trial.
Lead sponsor
Shenzhen People's Hospital
Phase
Not applicable
Overall status
Completed
Start date
January 12, 2020
Completion date
January 10, 2023
Enrollment
76 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

denosumab allergy, osteopenia, spine fusion